The price-to-earnings ratio for Novavax, Inc (NASDAQ: NVAX) is above average at 2.38x, Company’s 36-month beta value is 2.77.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for NVAX is 147.54M, and currently, short sellers hold a 30.30% ratio of that floaft. The average trading volume of NVAX on June 24, 2025 was 8.76M shares.
NVAX) stock’s latest price update
The stock price of Novavax, Inc (NASDAQ: NVAX) has jumped by 3728079 compared to previous close of 6.41. Despite this, the company has seen a fall of -9.08% in its stock price over the last five trading days. zacks.com reported 2025-06-20 that Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day’s close.
NVAX’s Market Performance
Novavax, Inc (NVAX) has experienced a -9.08% fall in stock performance for the past week, with a -11.25% drop in the past month, and a -16.97% drop in the past quarter. The volatility ratio for the week is 4.04%, and the volatility levels for the past 30 days are at 3.43% for NVAX. The simple moving average for the past 20 days is -10.07% for NVAX’s stock, with a -27.07% simple moving average for the past 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with Citigroup repeating the rating for NVAX by listing it as a “Sell.” The predicted price for NVAX in the upcoming period, according to Citigroup is $6 based on the research report published on June 17, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $19. The rating they have provided for NVAX stocks is “Buy” according to the report published on February 28th, 2025.
JP Morgan gave a rating of “Underweight” to NVAX, setting the target price at $8 in the report published on July 30th of the previous year.
NVAX Trading at -5.81% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.57% of loss for the given period.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.88 for the gross margin
The net margin for Novavax, Inc stands at 0.38. The total capital return value is set at 0.47.
Based on Novavax, Inc (NVAX), the company’s capital structure generated 1.49 points at debt to capital in total, while cash flow to debt ratio is standing at -0.83. The debt to equity ratio resting at -3.02. The interest coverage ratio of the stock is 40.17.
Currently, EBITDA for the company is -108.04 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 0.79. The receivables turnover for the company is 28.2for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.06.
Conclusion
In a nutshell, Novavax, Inc (NVAX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
